Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,706,561
  • Shares Outstanding, K 170,495
  • Annual Sales, $ 1,072 M
  • Annual Income, $ 391,000 K
  • EBIT $ 105 M
  • EBITDA $ 111 M
  • 60-Month Beta 0.83
  • Price/Sales 3.59
  • Price/Cash Flow 25.44
  • Price/Book 3.11

Options Overview Details

View History
  • Implied Volatility 53.69% (+12.92%)
  • Historical Volatility 45.20%
  • IV Percentile 60%
  • IV Rank 20.83%
  • IV High 127.33% on 04/16/25
  • IV Low 34.32% on 12/30/25
  • Expected Move (DTE 5) 0.47 (2.15%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 127
  • Volume Avg (30-Day) 265
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 11,216
  • Open Int (30-Day) 11,549
  • Expected Range 21.27 to 22.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.06
  • Number of Estimates 8
  • High Estimate $0.13
  • Low Estimate $-0.04
  • Prior Year $0.11
  • Growth Rate Est. (year over year) -45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.89 +9.30%
on 03/19/26
22.89 -5.02%
on 04/01/26
-0.80 (-3.55%)
since 03/10/26
3-Month
19.89 +9.30%
on 03/19/26
27.81 -21.83%
on 01/23/26
-5.04 (-18.82%)
since 01/09/26
52-Week
13.73 +58.34%
on 04/11/25
28.35 -23.32%
on 12/23/25
+7.63 (+54.08%)
since 04/10/25

Most Recent Stories

More News
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome...

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. ...

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company’s Audit Committee...

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted...

ACAD : 21.74 (-3.68%)
Acadia: Q4 Earnings Snapshot

Acadia: Q4 Earnings Snapshot

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year-over-year growth, respectively ...

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference...

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption.

ACAD : 21.74 (-3.68%)
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line...

ACAD : 21.74 (-3.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 23.59
2nd Resistance Point 23.09
1st Resistance Point 22.42
Last Price 21.74
1st Support Level 21.24
2nd Support Level 20.74
3rd Support Level 20.07

See More

52-Week High 28.35
Fibonacci 61.8% 22.77
Last Price 21.74
Fibonacci 50% 21.04
Fibonacci 38.2% 19.31
52-Week Low 13.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.